4th mRNA-Based Therapeutics Summit
Newsletters and Deep Dive digital magazine
Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
11-12 November 2024 in London, UK
Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running.